semaglutide glp-1 A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus | Diabetes Therapy GLP-1 Weight Loss Treatment (Semaglutide)

Description

Involvement of glucagon-like peptide-1 in the regulation of selective excretion of sodium or chloride ions by the kidneys

[PubMed] [Google Scholar] 178.Kuhre R.E., Albrechtsen N.W., Windelov J.A., Svendsen B., Hartmann B., Holst J.J

DOI: Published online: February 14, 2024 1 Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK 2 Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland Corresponding author: Adie Viljoen

The common thread

WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk